Portal de Periódicos da CAPES

Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study

2018; Ferrata Storti Foundation; Volume: 103; Issue: 5 Linguagem: Inglês

10.3324/haematol.2017.180893

1592-8721

Philipp Schommers, Daniel Gillor, Marcus Hentrich, Christoph Wyen, Timo Wolf, Mark Oette, Alexander Zoufaly, Jan‐Christian Wasmuth, Johannes R. Bogner, Markus Müller, Stefan Eßer, Alisa Schleicher, Björn‐Erik Ole Jensen, Albrecht Stoehr, Georg M. N. Behrens, Alexander Schultze, Jan Siehl, Jan Thoden, Ninon Taylor, Christian Hoffmann,

CNS Lymphoma Diagnosis and Treatment

Outcome of HIV-infected patients with AIDS-related lymphomas has improved during recent years. However, data on incidence, risk factors, and outcome of relapses in AIDS-related lymphomas after achieving complete remission are still limited. This prospective observational multicenter study includes HIV-infected patients with biopsy- or cytology-proven malignant lymphomas since 2005. Data on HIV infection and lymphoma characteristics, treatment and outcome were recorded. For this analysis, AIDS-related lymphomas patients in complete remission were analyzed in terms of their relapse- free survival and potential risk factors for relapses. In total, 254 of 399 (63.7%) patients with AIDS-related lymphomas reached a complete remission with their first-line chemotherapy. After a median follow up of 4.6 years, 5-year overall survival of the 254 patients was 87.8% (Standard Error 3.1%). Twenty-nine patients relapsed (11.4%). Several factors were independently associated with a higher relapse rate, including an unclassifiable histology, a stage III or IV according to the Ann Arbor Staging System, no concomitant combined antiretroviral therapy during chemotherapy and R-CHOP-based compared to more intensive chemotherapy regimens in Burkitt lymphomas. In conclusion, complete remission and relapse rates observed in our study are similar to those reported in HIV-negative non-Hodgkin lymphomas. These data provide further evidence for the use of concomitant combined antiretroviral therapy during chemotherapy and a benefit from more intensive chemotherapy regimens in Burkitt lymphomas. Modifications to the chemotherapy regimen appear to have only a limited impact on relapse rate.